Safeguard Scientifics Relaunches Website, Blog
Welcome to the newly redesigned Safeguard Scientifics blog! And if you haven’t been over to our website yet, check it out — we’ve transformed that…
Posted by
Welcome to the newly redesigned Safeguard Scientifics blog! And if you haven’t been over to our website yet, check it out — we’ve transformed that…
Posted by
Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…
Posted by
On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…
Posted by
James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…
Posted by
On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…
Posted by
While there are a wealth of opportunities to deploy capital in a variety of life sciences companies, the evolution and potential long-term impact of regenerative…
Posted by
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…
Posted by
I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…
Posted by
After spending the better part of the past two weeks meeting with money managers in financial centers throughout the Midwest and Southeast, it seems to…
Posted by